论文部分内容阅读
目的探讨小剂量米氮平联合疏肝解郁胶囊在脑卒中后抑郁症治疗中的应用效果。方法选择该院2012年10月-2014年10月收治的脑卒中后抑郁症患者200例,随机分为观察组和对照组各100例,观察组给予小剂量米氮平联合疏肝解郁胶囊治疗,对照组给予单纯疏肝解郁胶囊治疗。治疗后观察2组临床疗效,记录2组治疗过程中的不良发应发生情况。结果治疗后观察组脑卒中后抑郁症患者的总有效率为94%高于对照组的84%,差异有统计学意义(P<0.05)。2组脑卒中后抑郁症患者治疗过程中均未出现严重不良反应。结论小剂量米氮平联合疏肝解郁胶囊治疗脑卒中后抑郁症的临床疗效较好,安全性好,值得临床推广应用。
Objective To investigate the effect of low-dose mirtazapine combined with Shugan Jieyu capsule in the treatment of post-stroke depression. Methods A total of 200 patients with post-stroke depression who were admitted to our hospital from October 2012 to October 2014 were randomly divided into observation group (100 cases) and control group (100 cases). Mice in observation group were given low dose mirtazapine Treatment, control group given simple Shugan Jieyu capsule treatment. After treatment, the clinical efficacy of the two groups was observed, and the occurrence of adverse reactions in the two groups were recorded. Results After treatment, the total effective rate of post-stroke depression in the observation group was 94% higher than 84% in the control group, the difference was statistically significant (P <0.05). Two groups of post-stroke depression patients during treatment did not appear serious adverse reactions. Conclusion Low dose mirtazapine combined with Shugan Jieyu Capsule in the treatment of post-stroke depression has better clinical efficacy and safety, and is worthy of clinical application.